This study focuses on patients with progressive supranuclear palsy (PSP) who are over 40 years old. The purpose of the study is to evaluate an investigational drug called ABBV-8E12 and learn whether it could help slow down a disease called progressive supranuclear palsy (PSP). The study will also assess various doses of the drug and confirm its safety in patients with PSP.

Researchers aim to determine the effects that treatment with ABBV-8E12 will have on blood chemistry, cerebrospinal fluid, and clinical and biological markers of PSP. Information from brain magnetic resonance imaging (MRI) scans will also be collected to evaluate whether ABBV-8E12 appears to have an effect on the PSP disease process. Participants will be monitored carefully for side effects.

This website converts English to other languages using an automated tool called Microsoft Translator™. The translations may include errors or change the intended meaning of the text. Please consult your healthcare provider about any medical information.

Translations may not be available for some items, including PDF documents, maps, video captions, and text that appears on photos. Also, some features on the website may not work in the translated versions.

This Web page converts English to other languages â â using an automated tool called Microsoft Translatorâ ¢. Translations may include errors or change the intended meaning of the text. Please consult your doctor about any medical information.

Translations may not be available for some articles, including PDF documents, maps, video legends and text that appears in the photos. Also, some of the features on the website may not work in the translated versions.